Table 3.

Reasons for interruption of darunavir/cobicistat

	Dual therapy		Triple therapy		Total
	N = 72	%	N = 177	%	N = 249	%
Adverse events	1	1.4	12	6.8	13	5.2
Simplification/proactive switch	1	1.4	14	7.9	15	6.0
Patient’s preference/low adherence	2	2.8	6	3.4	8	3.2
Therapeutic failure	2	2.8	0	0.0	2	0.8
Death	0	0.0	2	1.1	2	0.8
Drug-drug interaction	1	1.4	3	1.7	4	1.6
Other reasons	1	1.4	1	0.6	2	0.8
Lost to follow-up	8	11.1	18	10.2	26	10.4